Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report report published on Monday morning,RTT News reports. Wedbush currently has a $11.00 price target on the stock.

A number of other equities analysts have also commented on the company. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Trading Up 0.4 %

Perspective Therapeutics stock opened at $2.60 on Monday. The business’s 50-day simple moving average is $3.12 and its 200-day simple moving average is $7.11. Perspective Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Perspective Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after purchasing an additional 11,472 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in Perspective Therapeutics during the fourth quarter valued at approximately $1,595,000. Squarepoint Ops LLC acquired a new stake in Perspective Therapeutics during the fourth quarter valued at approximately $626,000. Wexford Capital LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $64,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $484,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.